Whalesbook
Supriya Lifescience Reports Strong FY26 Performance
Supriya Lifescience announced its audited financial results for the full year ended March 31, 2026. The company's revenue from operations reached ₹827.87 crore, marking an 18.9% year-on-year increase. Profit After Tax (PAT) for the year grew 11.3% to ₹209.12 crore, with Earnings Per Share (EPS) at ₹25.98.
Revenue Surges on Strong Demand
The company saw substantial growth in the fourth quarter of FY26, with revenue surging 50.2% year-on-year to ₹276.53 crore. This strong quarterly performance contributed significantly to the full-year revenue increase, indicating robust demand for Supriya Lifescience's products.
Global Reach and Operational Efficiency
Supriya Lifescience's global presence is underscored by its high export share, which accounted for 82% of its revenue in FY26. Furthermore, its backward-integrated business model, contributing 76% of FY26 revenue, enhances supply chain stability and cost competitiveness in the pharmaceutical ingredients sector.
Margin Compression Amid Rising Costs
Despite strong revenue growth, the company experienced margin compression. EBITDA margins for FY26 declined by 192 basis points to 35.5%, and PAT margins fell to 25.3% from 27.0% in FY25. This was largely due to a 20.3% year-on-year increase in the Cost of Goods Sold (COGS), which grew faster than revenue. Investors will monitor how the company manages input costs and pricing to address this pressure.
Future Outlook
Supriya Lifescience plans to leverage its revenue momentum while focusing on cost management and pricing strategies. Ongoing capacity expansion and research and development efforts are expected to support future growth. Investors will be watching for margin improvements in upcoming quarters, effective cost control, and continued export expansion.